RZL can treat SS by downregulating the PI3K/AKT/mTOR signaling pathway, inhibiting the differentiation of Th17 cells, and reducing the level of IL-17 production; and the inflammatory microenvironment in the exocrine glands improved. Here, AKT1 is linked to synovial sarcoma.